Breast Cancer, Ductal Carcinoma in Situ, Invasive Breast Cancer
Conditions
Brief summary
Partial breast irradiation is typically performed after surgical removal of the tumor. Partial breast irradiation allows for focused radiation to the area from which the cancer was removed, sparing breast tissue from the potential bad effects of radiation compared to radiating the whole breast, which was the standard of care for many years. This study is evaluating the use of partial breast irradiation with NIBB performed before surgery instead of after surgery.This should allow researchers to target the cancer even more accurately and result in less normal breast tissue receiving radiation which may cause less side effects and/or a better cosmetic outcome. In this study partial breast treatment will be given with NIBB in 5 treatments over about 1 week. Surgical removal of the tumor will then be performed between 4-12 weeks following radiation treatment. Researchers believe that participant's risk of complications from surgery will not be higher after getting these radiation treatments than it would have been if participants had surgery first, but that is one of the things researchers are studying.
Interventions
RADIATIONNIBB: accuboost
28.5 Gy delivered in 5 daily fractions
PROCEDUREPartial mastectomy
4-12 weeks post NIBB
Sponsors
Brown University
Rhode Island Hospital
Women and Infants Hospital of Rhode Island
Jaroslaw Hepel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed histological diagnosis of invasive breast carcinoma and/or DCIS (Invasive lobular carcinoma excluded); * Age greater or equal to 60 years old; * Life expectancy \> 6 months; * Candidate for breast conserving surgery who intends to undergo breast conserving surgery as confirmed in writing by treating physician in consultation with surgeon * Clinically lymph node negative (cN0) as confirmed in writing by patient's treating physician. If patient has suspicious lymphadenopathy on imaging it is required that patient undergo a biopsy to confirm cN0. * Tumor size by imaging ≤ 2cm; (Tis or T1) * Estrogen receptor positive if invasive disease (DCIS can be ER negative); * Her2neu negative if invasive disease; * Nuclear Grade 1 or 2 if invasive disease (DCIS can be Grade 3); * ECOG performance status of 0-2 (Appendix 1); * Informed consent signed.
Exclusion criteria
* Excisional biopsy or ipsilateral breast surgery within 6 months; * Invasive lobular histology; * Definitive LVSI on biopsy; * Suspicious imaging findings suggesting multi-focal or multi-centric disease, unless biopsy proven benign; * Paget's disease of the nipple * Distant metastases; * Known BRCA 1/2 Mutation * Active lupus or scleroderma,; * Psychiatric or addictive disorder that would preclude attending follow-up; * Neoadjuvant chemotherapy or endocrine therapy (adjuvant therapy is permitted); * Breast Implants; * Tumor not well visualized on AccuBoost imaging; * Breast separation with compression \> 8cm at time of simulation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of APBI including rate of surgical complications. | Surgery will occur 4-12 weeks post NIBB treatment | — |
| Toxicity of pre-op APBI including rate of surgical complications. | Defined at up to 6 weeks post APBI | Defined as acute (during treatment and through 4 weeks post treatment) |
| Toxicity of surgical complications | Surgery to occur 4-12 weeks post radiation and post-op complications collected through 3 months post surgery | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess and report late toxicity | 6 weeks post treatment through 3 years | Late toxicity defined as 6 weeks post NIBB through 3 years in follow-up |
Outcome results
None listed